Company profile
Cyclerion Therapeutics, Inc.
NASDAQ: CYCN · Healthcare · Biotechnology
#789 of 1,418 Healthcare companies by revenue47th-percentile growth
EA Score
40DFH 31DQ 52GM 49SS 28
v0.1 · 65/100 weight · provisional
↑ filing timeliness, return on assets · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$2.0M
Rev growth YoY (TTM)
-4.2%
Net income (FY)
-$3.5M
Employees
1
as of 2026-08-22
Market cap
$18.2M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.1M$2.1M2025
Net income-$3.5M-$3.5M2025
Operating income-$5.0M-$5.0M2025
Total assets$10.0M$10.0M2025
Equity$9.1M$9.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
License Agreement88%
License13%
By geography
Not disclosed.
The read
What is Cyclerion Therapeutics, Inc.’s revenue?
Cyclerion Therapeutics, Inc. booked $2.1M in FY2025 revenue, growing 3.7% year over year — about the middle of the pack among Healthcare companies we track, at a -170.1% net margin.
Peers · Healthcare
BNB Plus Corp.33DGeneLink, Inc.——Aeolus Pharmaceuticals, Inc.——HealthLynked Corp.34D20/20 Biolabs Inc.30DHumacyte, Inc.27DNeighbors
Middlesex →Key facts
CEORegina Graul
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: CYCN
Employees1
IPO date2019-03-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.